Increasing recognition and emerging therapies argue for dedicated clinical trials in chronic myelomonocytic leukemia

A Renneville, MM Patnaik, O Chan, E Padron, E Solary - Leukemia, 2021 - nature.com
Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell disorder with
overlapping features of myelodysplastic syndromes (MDS) and myeloproliferative …
被引用次数：14 相关文章

Increasing recognition and emerging therapies argue for dedicated clinical trials in chronic myelomonocytic leukemia.

A Renneville, MM Patnaik, O Chan, E Padron, E Solary - Leukemia, 2021 - europepmc.org
Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell disorder with
overlapping features of myelodysplastic syndromes (MDS) and myeloproliferative …

Increasing recognition and emerging therapies argue for dedicated clinical trials in chronic myelomonocytic leukemia

A Renneville, MM Patnaik, O Chan… - …, 2021 - mayoclinic.elsevierpure.com
Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell disorder with
overlapping features of myelodysplastic syndromes (MDS) and myeloproliferative …

Increasing recognition and emerging therapies argue for dedicated clinical trials in chronic myelomonocytic leukemia

A Renneville, MM Patnaik, O Chan, E Padron… - …, 2021 - pubmed.ncbi.nlm.nih.gov
Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell disorder with
overlapping features of myelodysplastic syndromes (MDS) and myeloproliferative …

[引用][C] Increasing recognition and emerging therapies argue for dedicated clinical trials in chronic myelomonocytic leukemia

A Renneville, M Patnaik, O Chan, E Padron, É Solary - Leukemia, 2021 - hal.science
Increasing recognition and emerging therapies argue for dedicated clinical trials in chronic
myelomonocytic leukemia - Archive ouverte HAL Accéder directement au contenu …